LNSR Research | Milton Maxwell

LNSR

LENSAR, Inc.

12.06

+0.54+4.69%

Dec 16, 4:00:01 PM EST

Upcoming Earnings

Report date

-/-

Earnings Call Transcripts

This Quarter (Q1 '26)

No earnings call transcript available yet

Last Quarter (Q4 '25)

FY Q4 '25

3/30/26Mar 30, 2026

Key Stats

Market Cap

144.05M

P/E (TTM)

Basic EPS (TTM)

-4.37

Dividend Yield

Recent Filings

8-K

LENSAR-Alcon deal update

2/25/26Feb 25, 2026

LENSAR updated on its pending acquisition by Alcon Research, LLC, noting ongoing cooperation with FTC staff on the Second Request review. Closure now eyed for H1 2026, pending regulatory approval and conditions. Deal risks persist, including FTC delays or termination.

8-K

LENSAR elects directors, ratifies auditors

12/19/25Dec 19, 2025

LENSAR stockholders overwhelmingly elected Nicholas T. Curtis, Todd B. Hammer, and Aimee S. Weisner as Class II directors at the December 18, 2025 annual meeting, with each receiving over 14 million FOR votes amid 2 million withheld and broker non-votes. Ratification of PricewaterhouseCoopers as auditors passed decisively, 17.5 million FOR versus just 33,000 against. Board continuity locked in.

8-K

Q3 revenue up 6%

11/6/25Nov 6, 2025

LENSAR posted Q3 revenue of $14.3M, up 6% from $13.5M last year, fueled by 11% higher procedure volume and 18 new ALLY system placements that boosted its ALLY base 77% year-over-year to 185 units. Total laser installed base hit 425, up 20%, while recurring revenue share climbed to 75%. Alcon acquisition costs spiked SG&A 98%; deal now eyes Q1 2026 close amid FTC review. Cash dipped to $16.9M.

10-Q

Q3 FY2025 results

11/6/25Nov 6, 2025

LENSAR posted Q3 revenue of $14.3M, up 6% y/y from $13.5M but flat q/q (derived), fueled by higher procedure volume while product costs climbed 26% y/y to $5.6M from tariff and inflation hits. Operating loss widened to $7.6M from $1.2M y/y due to $5.3M in acquisition costs tied to the pending Alcon merger (announced March 2025, $14/share cash plus $2.75 CVR, $10M deposit received, Q1 2026 close eyed amid FTC review); net loss narrowed to $3.7M from $1.5M y/y thanks to $3.7M warrant fair-value gain. Cash dipped to $7.6M plus $9.2M short-term investments, with $15.4M YTD operating cash burn; no debt. Merger distraction risks persist.

8-K

2025 meeting scheduled, merger-dependent

10/21/25Oct 21, 2025

Lensar scheduled its 2025 annual stockholder meeting for December 18, 2025, virtually, but only if the pending Alcon merger doesn't close first. Record date is October 24; proposals and nominations due by October 31 to meet bylaws and SEC rules. Merger risks could nix the vote entirely.

About

LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism in the United System. The company offers LENSAR Laser System which incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes by providing imaging, procedure planning, design, and precision. It also provides ALLY Robotic Cataract Laser System, a compact cataract treatment system that is designed to allow surgeons to perform sterile laser-assisted cataract surgery in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.

CEO

Mr. Nicholas T. Curtis

IPO

10/2/2020

Website

https://www.lensar.com

Employees

140

Sector

Healthcare

Industry

Medical Devices